In the News
Confluence Announces Israel has Issued a New Patent for its Sprinkle Technology for the Treatment of Fragile X Syndrome and Autism Spectrum Disorders
Enriched Data Set Analysis of Double-Blind Placebo-Controlled Study of Acamprosate Treatment for Fragile X Syndrome Demonstrates Improvements Across Several Disorder-Relevant Domains including Expressive Language, Social Engagement, Anxiety and Hyperactivity
Indiana University Philanthropic Venture Fund Makes $200,000 Follow-On Investment in Confluence Pharmaceuticals
Confluence Announces Issuance of a New Japanese Patent for its Sprinkle Technology for the Treatment of Fragile X Syndrome and Autism Spectrum Disorders
Confluence Pharmaceuticals Receives Follow-On Investments for its Bridge Round Offering from Foundry Investment Fund ($250,000) and Indiana 21st Century Fund ($250,000)
Confluence Receives a Second Patent Issuance in Australia Expanding its Sprinkle Formulation Portfolio
Confluence Announces Issuance of a New Patent in the South Africa for its Sprinkle Formulation Technology Treating Fragile X Syndrome and Autism
Confluence is Granted a Patent in South Africa for its Combination Therapy Using Acamprosate and D-Cycloserine to Treat Neurological & Cognitive Conditions
Confluence Announces the Addition of Don Bailey, PhD to Scientific Advisory Board and Patient Advocate Advisory Board
Inside Indiana Business News: Fragile X Treatment Nears Phase 2 Trials
https://www.insideindianabusiness.com/articles/fragile-x-treatment-nears-phase-2-trials
Confluence Sponsors FRAXA's World Fragile X Syndrome Day Celebration on July 22, 2021
Confluence is Granted a Patent in Australia for its Sprinkle Formulation Technology Treating Fragile X Syndrome and Autism Spectrum Disorders
Indiana University Philanthropic Venture Fund Makes $100,000 Follow-On Investment in Confluence Pharmaceuticals
https://news.iu.edu/stories/2020/12/iu/02-philanthropic-venture-fund-invests-confluence-pharmaceuticals.html
Confluence Announces Issuance of a New U.S. Patent for its Sprinkle Technology for the Treatment of Fragile X Syndrome and Autism Spectrum Disorders
Confluence Pharmaceuticals Receives $200,000 Investment from Indiana University Philanthropic Venture Fund
news.iu.edu/stories/2019/04/iu/11-confluence-pharmaceuticals-autism-fragile-x-investment-philanthropic-venture-fund.html
Confluence Pharmaceuticals Receives $250,000 Investment from Foundry Investment Fund www.purdue.edu/newsroom/releases/2018/Q4/purdue-foundry-investment-fund-provides-750,000-to-advance-3-life-sciences-startups.html
Confluence Pharmaceuticals Completes Successful Phase I Clinical Trial for Fragile X Syndrome Drug
Press Release
Confluence Pharmaceuticals Completes $1.3 Million Series A-2 Financing www.elevateventures.com/biopharmaceutical-company-confluence-pharmaceuticals-completes-1-3-million-series-a-2-financing/
Confluence Pharmaceuticals Signs Co-Development and Marketing Agreement with AOP Orphan Pharmaceuticals for Fragile X Drug
Press Release
Confluence Receives European Orphan Drug Designation for Fragile X Syndrome
http://ec.europa.eu/health/documents/community-register/html/orphreg.htm
National Fragile X Research Foundation Recognizes Dr. Craig Erickson for Outstanding Research and Clinical Service to Worldwide Fragile X Community
http://www.fragilex.org/2014/International-fragile-x-conference/2014-conference-award
Confluence Receives U.S. Orphan Drug Designation for Fragile X Syndrome
http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?index_Number=392413
The John Merck Fund Awards Dr. Erickson $1 Million Research Grant| Acamprosate for FXS
http://www.fragilex.org/2013/foundation/press-release/merck-fund
Autism Speaks Funds Dr. Erickson's Research | Acamprosate for ASD with TrailBlazer Award
http://www.autismspeaks.org/science/grants/acamprosate-youth-autism-spectrum-disorders
VIDEO | Standards for Diagnosing Autism Under Review. NBC News Interview
http://today.msnbc.msn.com/id/26184891/vp/47827711#47827711
Bioscience Technology | Fragile X Gene’s Prevalence Suggests Broader Health Risk
http://www.biosciencetechnology.com/News/2012/06/
VIDEO | Study Shows 1 in 88 Have Autism. Fox59 News Interview with Dr. Craig Erickson
http://www.fox59.com/videogallery/69120370/News/VIDEO-Study-Shows-1-in-8-Have-Autism
Indianapolis Star Interview | Rising Star- Dr. Craig Erickson
http://www.indystar.com/article/20110417/BUSINESS/304170026/Rising-Star-Dr-Craig-Erickson-autism-specialist
Dr. Craig Erickson Discusses the Drug Acamprosate for the Treatment of Fragile X
http://nfxf.blogspot.com/2011/05/dr-craig-erickson-discusses-drug.html
Article & VIDEO | Indy Doctors Treat Autism With Alcoholism Drug
http://www.theindychannel.com/news/27627926/detail.html
NCB Affiliate WTHR13 | New study uses alcoholism treatment for Fragile X
http://www.wthr.com/story/14360796/new-study-uses-alcoholism-treatment-for-fragile-x?client
Enriched Data Set Analysis of Double-Blind Placebo-Controlled Study of Acamprosate Treatment for Fragile X Syndrome Demonstrates Improvements Across Several Disorder-Relevant Domains including Expressive Language, Social Engagement, Anxiety and Hyperactivity
Indiana University Philanthropic Venture Fund Makes $200,000 Follow-On Investment in Confluence Pharmaceuticals
Confluence Announces Issuance of a New Japanese Patent for its Sprinkle Technology for the Treatment of Fragile X Syndrome and Autism Spectrum Disorders
Confluence Pharmaceuticals Receives Follow-On Investments for its Bridge Round Offering from Foundry Investment Fund ($250,000) and Indiana 21st Century Fund ($250,000)
Confluence Receives a Second Patent Issuance in Australia Expanding its Sprinkle Formulation Portfolio
Confluence Announces Issuance of a New Patent in the South Africa for its Sprinkle Formulation Technology Treating Fragile X Syndrome and Autism
Confluence is Granted a Patent in South Africa for its Combination Therapy Using Acamprosate and D-Cycloserine to Treat Neurological & Cognitive Conditions
Confluence Announces the Addition of Don Bailey, PhD to Scientific Advisory Board and Patient Advocate Advisory Board
Inside Indiana Business News: Fragile X Treatment Nears Phase 2 Trials
https://www.insideindianabusiness.com/articles/fragile-x-treatment-nears-phase-2-trials
Confluence Sponsors FRAXA's World Fragile X Syndrome Day Celebration on July 22, 2021
Confluence is Granted a Patent in Australia for its Sprinkle Formulation Technology Treating Fragile X Syndrome and Autism Spectrum Disorders
Indiana University Philanthropic Venture Fund Makes $100,000 Follow-On Investment in Confluence Pharmaceuticals
https://news.iu.edu/stories/2020/12/iu/02-philanthropic-venture-fund-invests-confluence-pharmaceuticals.html
Confluence Announces Issuance of a New U.S. Patent for its Sprinkle Technology for the Treatment of Fragile X Syndrome and Autism Spectrum Disorders
Confluence Pharmaceuticals Receives $200,000 Investment from Indiana University Philanthropic Venture Fund
news.iu.edu/stories/2019/04/iu/11-confluence-pharmaceuticals-autism-fragile-x-investment-philanthropic-venture-fund.html
Confluence Pharmaceuticals Receives $250,000 Investment from Foundry Investment Fund www.purdue.edu/newsroom/releases/2018/Q4/purdue-foundry-investment-fund-provides-750,000-to-advance-3-life-sciences-startups.html
Confluence Pharmaceuticals Completes Successful Phase I Clinical Trial for Fragile X Syndrome Drug
Press Release
Confluence Pharmaceuticals Completes $1.3 Million Series A-2 Financing www.elevateventures.com/biopharmaceutical-company-confluence-pharmaceuticals-completes-1-3-million-series-a-2-financing/
Confluence Pharmaceuticals Signs Co-Development and Marketing Agreement with AOP Orphan Pharmaceuticals for Fragile X Drug
Press Release
Confluence Receives European Orphan Drug Designation for Fragile X Syndrome
http://ec.europa.eu/health/documents/community-register/html/orphreg.htm
National Fragile X Research Foundation Recognizes Dr. Craig Erickson for Outstanding Research and Clinical Service to Worldwide Fragile X Community
http://www.fragilex.org/2014/International-fragile-x-conference/2014-conference-award
Confluence Receives U.S. Orphan Drug Designation for Fragile X Syndrome
http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?index_Number=392413
The John Merck Fund Awards Dr. Erickson $1 Million Research Grant| Acamprosate for FXS
http://www.fragilex.org/2013/foundation/press-release/merck-fund
Autism Speaks Funds Dr. Erickson's Research | Acamprosate for ASD with TrailBlazer Award
http://www.autismspeaks.org/science/grants/acamprosate-youth-autism-spectrum-disorders
VIDEO | Standards for Diagnosing Autism Under Review. NBC News Interview
http://today.msnbc.msn.com/id/26184891/vp/47827711#47827711
Bioscience Technology | Fragile X Gene’s Prevalence Suggests Broader Health Risk
http://www.biosciencetechnology.com/News/2012/06/
VIDEO | Study Shows 1 in 88 Have Autism. Fox59 News Interview with Dr. Craig Erickson
http://www.fox59.com/videogallery/69120370/News/VIDEO-Study-Shows-1-in-8-Have-Autism
Indianapolis Star Interview | Rising Star- Dr. Craig Erickson
http://www.indystar.com/article/20110417/BUSINESS/304170026/Rising-Star-Dr-Craig-Erickson-autism-specialist
Dr. Craig Erickson Discusses the Drug Acamprosate for the Treatment of Fragile X
http://nfxf.blogspot.com/2011/05/dr-craig-erickson-discusses-drug.html
Article & VIDEO | Indy Doctors Treat Autism With Alcoholism Drug
http://www.theindychannel.com/news/27627926/detail.html
NCB Affiliate WTHR13 | New study uses alcoholism treatment for Fragile X
http://www.wthr.com/story/14360796/new-study-uses-alcoholism-treatment-for-fragile-x?client